Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07537777) titled 'Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy' on April 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Nanfang Hospital, Southern Medical University
Condition:
Hepatocellular Carcinoma (HCC)
First-line Targeted Therapy Failure
Oligometastatic Hepatocellular Carcinoma
Benmelstobart
Anlotinib
SBRT
Intervention:
Drug: Benmelstobart
Procedure: SBRT
Recruitment Status: Not recruiting
Phase: Phase 2
Da...